PassionIT News

FLORHAM PARK, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune^® T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021. 

Read More at:

https://www.globenewswire.com/news-release/2021/07/28/2270281/37149/en/PDS-Biotechnology-to-Present-Recent-Phase-2-Human-Clinical-Data-and-On-Going-Oncology-Programs-at-Investor-Conferences.html